title: Reduced cerebrospinal fluid levels of immunoreactive pro-opiomelanocortin related peptides (including beta-endorphin) in anorexia nervosa.
abstract: The discovery that the endogenous opioid peptides contribute to the modulation of appetitive behavior and neuroendocrine function has raised questions as to whether disturbances of opioids contributes to the pathophysiology of eating disorders. To assess central nervous system (CNS) beta-endorphin in patients with anorexia nervosa we measured cerebrospinal fluid (CSF) beta-endorphin concentrations before, and at intervals after weight correction. In addition, we measured three sister peptides (beta-lipotropin, adrenocorticotropic hormone (ACTH), and the N-terminal fragment) derived from the same precursor molecule, pro-opiomelanocortin (POMC) to determine whether possible disturbances might extend to sister peptides. Underweight anorectics (58 +/- 5% of average body weight (ABW), n = 10) had significantly lower CSF concentrations of all 4 peptides compared to healthy controls (102 +/- 10% ABW, n = 11). CSF concentrations of all 4 POMC-related peptides were found to be significantly increased when the same anorectics were restudied 4 to 6 weeks after weight gain (83 +/- 4% ABW). After weight gain, levels of CSF beta-endorphin, beta-lipotropin, and ACTH were similar to controls, whereas levels of CSF N-POMC remained significantly less than controls. Another group of women, previously underweight with anorexia nervosa, but weight-restored (93 +/- 11% ABW, n = 12) for greater than 1 year had CSF concentrations of all 4 POMC-related peptides that were similar to controls. We conclude that underweight anorectics have state-associated disturbances of CNS beta-endorphin as well as other POMC-related peptides. These abnormalities are part of the neurobiological syndrome of anorexia nervosa and may contribute to the characteristic alterations in behavior and neuroendocrine function.
authors.affiliation: University of Pittsburgh, Western Psychiatric Institute and Clinic, PA 15213.
authors.forename: W H
authors.initials: WH
authors.lastname: Kaye
authors.forename: W H
authors.initials: WH
authors.lastname: Berrettini
authors.forename: H E
authors.initials: HE
authors.lastname: Gwirtsman
authors.forename: M
authors.initials: M
authors.lastname: Chretien
authors.forename: P W
authors.initials: PW
authors.lastname: Gold
authors.forename: D T
authors.initials: DT
authors.lastname: George
authors.forename: D C
authors.initials: DC
authors.lastname: Jimerson
authors.forename: M H
authors.initials: MH
authors.lastname: Ebert
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000134:cerebrospinal fluid; D000328:Adult; D000856:Anorexia Nervosa / Q000134:cerebrospinal fluid*; D001835:Body Weight; D005260:Female; D006801:Humans; D010446:Peptide Fragments / Q000134:cerebrospinal fluid; D011333:Pro-Opiomelanocortin / Q000134:cerebrospinal fluid*; D001615:beta-Endorphin / Q000134:cerebrospinal fluid*; D008083:beta-Lipotropin / Q000134:cerebrospinal fluid
chemical_list: D010446:Peptide Fragments; D001615:beta-Endorphin; D011333:Pro-Opiomelanocortin; D000324:Adrenocorticotropic Hormone; D008083:beta-Lipotropin